Phase 2 Glioblastoma Study Shows Improved Progression Free Survival
California-based AIVITA Biomedical, Inc. recently announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM). The analysis focused on 57 patients scheduled to receive up to eight doses of AV-GBM-1 over approximately six months.
At the time of the analysis in 2020, surviving patients had completed therapy and had been followed between 7.2 and 24.2 months. The median length of progression-free survival was 10.0 months (95% CI 8.5 to 11.5 months), an improvement of approximately 45% compared to a median of 6.9 months (95% CI 5.8 to 8.2 months) progression-free survival in the landmark study that established the standard of care for patients with newly diagnosed GBM.
This represented a 38% reduction in risk of progression or death at 6.9 months of treatment.
“The improvement in GBM patients who were treated with AV-GBM-1, compared to studies with the standard of care, is a very promising indication that our therapy confers a benefit to patients in need,” commented Robert O. Dillman, M.D., chief medical officer of AIVITA, in a press statement.
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines.